Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
The pharmaceutical company’s Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a ‘state-of-the-art’ facility.
The pharmaceutical firm has tapped the decentralized research organization in order to help elevate the inclusivity of its oncology trials at all levels.
Eli Lilly and Company and Banner Alzheimer’s Institute have announced a strategic research collaboration as part of the planned Phase 3 study for donanemab in participants at risk from cognitive and functional decline related to Alzheimer’s disease.
The past several days have seen a relatively large number of industry acqusitions, with Lilly, Phillip Morris, WCG, CTI and others making notable buys.
The US agency continues to keep a watchful eye over the nation’s pandemic response, issuing advice to professionals and taking action where appropriate.
The agency has given the go-ahead for use of baricitinib in conjunction with remdesivir for treating patients hospitalized with severe cases of the virus.
Courts continue to rule in favor of Lilly’s lung cancer treatment patent, as the District Court for Appeals concludes generic producers like Dr Reddy’s to be potentially infringing.
Pharma and regulators are using machine learning to accelerate various pharmacovigilance activities – as the number of adverse event reports increases 10-12% each year, says Eli Lilly advisor.
Atomwise signs a multi-year agreement with Eli Lilly and Company through which it will apply its patented artificial intelligence technology to support Lilly’s preclinical drug discovery efforts.
Parexel and Eli Lilly are launching a clinical research learning and development program in China as recent reforms have “dramatically” increased the need for new sites in the country.
Eli Lilly is scaling back manufacturing of Cymbalta but says there will be no major loss of production jobs as a number of firms begin producing generic versions.
The FDA has issued Eli Lilly with a warning letter detailing a significant deviation from cGMP at its API production facility in Puerto Rico, which makes ingredients used in Humalog (insulin lispro), a diabetes treatment.
Eli Lilly has agreed to acquire ImClone for $6.5bn and in doing so appears to have snatched the biotech away from Bristol-Myers Squibb (BMS), which first tabled a bid back in July.
The future of Eli Lilly's API manufacturing facility in Lafayette, Indiana has been thrown into doubt by the news the company is considering selling it.
A recent study conducted by Eli Lilly's research laboratories
division suggests that quantitative ion mobility spectrometry
(qIMS) can offer drugmakers a rapid on-site means of verifying the
cleanliness of manufacturing equipment.
Eli Lilly plans to cut 500 jobs, mainly in manufacturing, as it
attempts to restructure its operations to mitigate against the
losses from inhaled insulin.
US-based drug delivery specialist Alkermes is cutting its losses
following Eli Lilly's decision to scrap the companies' joint
development programme for inhaled insulin.
Chemical and intermediates firm Lanxess has announced that its
subsidiary Saltigo is the proud new owner of a site in Washington
in the US, formerly used by Eli Lilly subsidiary, ICOS.
Procter & Gamble (P&G) has this week terminated an
agreement with Nastech to develop a nasally delivered version of
Eli Lilly's osteoporosis drug Forteo (teriparatide), leaving its
partner with no explanation for the...
Eli Lilly has agreed to fork out $18m (€12.8m) to settle an ongoing
lawsuit with one of its former biotech research partners and in
doing so has avoided a court battle earmarked for next year.
Amylin Pharmaceuticals is expanding significantly on the US
manufacturing facility it is building in West Chester, Ohio for a
long-acting version of its injectable diabetes drug Byetta
(exenatide).
Giant drug manufacturer Eli Lilly last week announced a reshuffle
in its global manufacturing operations to reflect the company's
focus on its current product portfolio and drug pipeline.
Giant drug maker Eli Lilly has confirmed that it will be closing
its manufacturing facility in Basingstoke, England, resulting in
$85m to $95m in restructuring costs for the company.
Eli Lilly has splashed out $2.1bn (€1.7bn) to buy ICOS, who the
drug giant has been involved in a joint venture with to manufacture
and sell Cialis (tadalafil) - the number two erectile dysfunction
drug behind Viagra (sildenafil).
A cartridge shortage that forced Amylin and Eli Lilly to ask 40,000
physicians in the US to stop prescribing their injectable diabetes
drug Byetta to new patients has come to an end thanks to a boost in
production by contract manufacturer...
Determined to slash operational costs, Eli Lilly has decided to
shut down its pill and tablet manufacturing plant in Basingstoke
and boost production in its remaining three dry product sites.
SciGen are to establish a manufacturing facility in China in a
response to the growing demand for the Hepatitis B (HBV) vaccine
and insulin, which has reached epidemic proportions with 2 billion
people having become infected with...
US drug company, Eli Lilly, offered a more encouraging outlook than
was expected forecasting an earnings growth of up to 12 per cent, a
stark contrast to its struggling competitors, who also face generic
competition, drug safety and...
US drug company, Eli Lilly, offered a more encouraging outlook than
was expected forecasting an earnings growth of up to 12 per cent, a
stark contrast to its struggling competitors, who also face generic
competition, drug safety and...
Drug delivery specialist SCOLR Pharma has started pilot testing in
Canada of a formulation of the osteoporosis drug raloxifene that
promises to improve the absorption of the drug and, potentially,
hike its efficacy, reports Phil Taylor.
A case currently going through the European Court of Justice could
have worrying implications for companies that use reformulation and
drug delivery as a way to extend the patented lifespan of their
drugs.
Ireland's Elan has signed its first major contract manufacturing
and supply agreement in a development that reinforces its
credentials as a player in the outsourcing sector.
Hyderabad, India-based Dr Reddy's Laboratories has reported
revenues of 5.1 billion rupees (€89m) in the third quarter of
fiscal 2004, up 18 per cent and ahead of analysts' forecasts.
Emisphere Technologies has demonstrated effective oral delivery of
protein-based drugs in three studies presented at the Controlled
Release Society's annual meeting.
